MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

AbbVie Inc

Затворен

СекторЗдравеопазване

189.23 -1.23

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

188.52

Максимум

189.89

Ключови измерители

By Trading Economics

Приходи

1.3B

1.3B

Продажби

-1.8B

13B

P/E

Средно за сектора

81.846

39.857

EPS

2.46

Дивидентна доходност

3.53

Марж на печалбата

9.66

Служители

55,000

EBITDA

3.2B

3.7B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+10.83% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.53%

2.42%

Следващи печалби

31.07.2025 г.

Следваща дата на дивидент

15.08.2025 г.

Следваща дата на екс-дивидент

14.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-5B

338B

Предишно отваряне

190.46

Предишно затваряне

189.23

Настроения в новините

By Acuity

24%

76%

51 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.06.2025 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25.04.2025 г., 13:57 ч. UTC

Печалби

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25.04.2025 г., 12:52 ч. UTC

Печалби

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9.04.2025 г., 18:18 ч. UTC

Значими двигатели на пазара

Pharma Shares Reverse Losses After Tariff Pause

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30.06.2025 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30.06.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30.06.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30.06.2025 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30.06.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7.05.2025 г., 09:30 ч. UTC

Топ новини

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28.04.2025 г., 12:44 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28.04.2025 г., 09:33 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 16:03 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 14:00 ч. UTC

Топ новини
Печалби

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 12:24 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 12:03 ч. UTC

Топ новини
Печалби

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Net $1.29B >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q EPS 72c >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Adj EPS $2.46 >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q Rev $13.34B >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3.03.2025 г., 15:04 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

10.83% нагоре

12-месечна прогноза

Среден 212.13 USD  10.83%

Висок 250 USD

Нисък 170 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

12

Купи

6

Задържане

0

Продай

Техническа оценка

By Trading Central

180.37 / 195.54Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

51 / 376 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.